Cargando…

Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma

BACKGROUND: Thymoma and thymic carcinoma are rare thymic epithelial tumors. We investigated the efficacy of first‐line gemcitabine and cisplatin (GP) chemotherapy versus gemcitabine and cisplatin chemotherapy combined with the anti‐angiogenic drug endostar (GP + E) in advanced thymoma and thymic car...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yang, Nie, Jun, Dai, Ling, Hu, Weiheng, Chen, Xiaoling, Han, Jindi, Ma, Xiangjuan, Tian, Guangming, Han, Sen, Long, Jieran, Zhang, Ziran, Fang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312837/
https://www.ncbi.nlm.nih.gov/pubmed/30411854
http://dx.doi.org/10.1111/1759-7714.12891
_version_ 1783383832753340416
author Wang, Yang
Nie, Jun
Dai, Ling
Hu, Weiheng
Chen, Xiaoling
Han, Jindi
Ma, Xiangjuan
Tian, Guangming
Han, Sen
Long, Jieran
Zhang, Ziran
Fang, Jian
author_facet Wang, Yang
Nie, Jun
Dai, Ling
Hu, Weiheng
Chen, Xiaoling
Han, Jindi
Ma, Xiangjuan
Tian, Guangming
Han, Sen
Long, Jieran
Zhang, Ziran
Fang, Jian
author_sort Wang, Yang
collection PubMed
description BACKGROUND: Thymoma and thymic carcinoma are rare thymic epithelial tumors. We investigated the efficacy of first‐line gemcitabine and cisplatin (GP) chemotherapy versus gemcitabine and cisplatin chemotherapy combined with the anti‐angiogenic drug endostar (GP + E) in advanced thymoma and thymic carcinoma. METHODS: The records of 45 patients with invasive metastatic thymomas or thymic carcinomas treated with GP as first‐line therapy between August 2008 and July 2017 at the Department of Respiratory Medicine, Peking University Cancer Hospital and Institute were retrospectively reviewed. RESULTS: Eighteen patients (75%) in the GP + E group achieved a partial response and six (25%) had stable disease. In GP only group, nine (42.8%) patients achieved a partial response, 11 (52.4%) had stable disease, and one (4.8%) had progressive disease. The GP + E group had a significantly higher overall response rate (75% vs. 42.9%; P = 0.028), and median progression‐free survival (PFS) and overall survival (OS) of 19 and 76 months, respectively. In the GP only group, median PFS and OS were 16 and 29 months, respectively. PFS and OS were not significantly different between the groups. CONCLUSIONS: GP has moderate efficacy and could represent a suitable first‐line therapy for thymic carcinoma and thymoma. Chemotherapy combined with endostar could improve the overall response rate, but did not prolong PFS or OS.
format Online
Article
Text
id pubmed-6312837
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-63128372019-01-07 Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma Wang, Yang Nie, Jun Dai, Ling Hu, Weiheng Chen, Xiaoling Han, Jindi Ma, Xiangjuan Tian, Guangming Han, Sen Long, Jieran Zhang, Ziran Fang, Jian Thorac Cancer Original Articles BACKGROUND: Thymoma and thymic carcinoma are rare thymic epithelial tumors. We investigated the efficacy of first‐line gemcitabine and cisplatin (GP) chemotherapy versus gemcitabine and cisplatin chemotherapy combined with the anti‐angiogenic drug endostar (GP + E) in advanced thymoma and thymic carcinoma. METHODS: The records of 45 patients with invasive metastatic thymomas or thymic carcinomas treated with GP as first‐line therapy between August 2008 and July 2017 at the Department of Respiratory Medicine, Peking University Cancer Hospital and Institute were retrospectively reviewed. RESULTS: Eighteen patients (75%) in the GP + E group achieved a partial response and six (25%) had stable disease. In GP only group, nine (42.8%) patients achieved a partial response, 11 (52.4%) had stable disease, and one (4.8%) had progressive disease. The GP + E group had a significantly higher overall response rate (75% vs. 42.9%; P = 0.028), and median progression‐free survival (PFS) and overall survival (OS) of 19 and 76 months, respectively. In the GP only group, median PFS and OS were 16 and 29 months, respectively. PFS and OS were not significantly different between the groups. CONCLUSIONS: GP has moderate efficacy and could represent a suitable first‐line therapy for thymic carcinoma and thymoma. Chemotherapy combined with endostar could improve the overall response rate, but did not prolong PFS or OS. John Wiley & Sons Australia, Ltd 2018-11-09 2019-01 /pmc/articles/PMC6312837/ /pubmed/30411854 http://dx.doi.org/10.1111/1759-7714.12891 Text en © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Wang, Yang
Nie, Jun
Dai, Ling
Hu, Weiheng
Chen, Xiaoling
Han, Jindi
Ma, Xiangjuan
Tian, Guangming
Han, Sen
Long, Jieran
Zhang, Ziran
Fang, Jian
Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
title Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
title_full Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
title_fullStr Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
title_full_unstemmed Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
title_short Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
title_sort efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312837/
https://www.ncbi.nlm.nih.gov/pubmed/30411854
http://dx.doi.org/10.1111/1759-7714.12891
work_keys_str_mv AT wangyang efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma
AT niejun efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma
AT dailing efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma
AT huweiheng efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma
AT chenxiaoling efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma
AT hanjindi efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma
AT maxiangjuan efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma
AT tianguangming efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma
AT hansen efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma
AT longjieran efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma
AT zhangziran efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma
AT fangjian efficacyandtoxicitiesofgemcitabineandcisplatincombinedwithendostarinadvancedthymomaandthymiccarcinoma